Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Wallin et al.
Nature Communications
Papers
August 2016
Authors and Affiliates
Jeffrey J. Wallin1, Johanna C. Bendell2, Roel Funke1, Mario Sznol3, Konstanty Korski4, Suzanne Jones2, Genevive Hernandez1, James Mier5, Xian He1, F. Stephen Hodi6, Mitchell Denker1, Vincent Leveque1, Marta Canamero4, Galina Babitski4, Hartmut Koeppen1, James Ziai1, Neeraj Sharma1, Fabien Gaire4, Daniel S. Chen1, Daniel Waterkamp1, Priti S. Hegde1 & David F. McDermott5
1 Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, USA. 2 GI Oncology Research, Drug Development Unit, Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, Tennessee, 37203, USA. 3 Department of Internal Medicine and Melanoma Unit, Yale Cancer Center, New Haven, Connecticut 06511, USA. 4 Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany. 5 Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusets 02215, USA. 6 Dana-Farber/Brigham and Women’s Cancer Center, 450 Brookline Avenue, Boston, Massachusets 02215, USA.